Posttransplant monitoring of pediatric lung transplant recipients

Current Opinion in Pediatrics

Volumn 19, Issue 3, 2007, Pages 321-326

  Visner, Gary A ^a,b   Goldfarb, Samuel B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Diagnostic tests; Lung transplant; Patient care; Pediatric

Indexed keywords

ALLOANTIBODY; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CYCLOSPORIN; HLA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ANTIBIOTIC PROPHYLAXIS; ANTIBODY DETECTION; AREA UNDER THE CURVE; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; CHILDHOOD MORTALITY; CHRONIC GRAFT REJECTION; CYTOMEGALOVIRUS INFECTION; DEVICE; DRUG METABOLISM; DRUG MONITORING; ENZYME LINKED IMMUNOSPOT ASSAY; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GRAFT RECIPIENT; HERPES SIMPLEX; HERPES VIRUS INFECTION; HISTOCOMPATIBILITY GENE; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LABORATORY TEST; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MORBIDITY; MYCOSIS; PATIENT MONITORING; PEDIATRIC SURGERY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; STOMACH FUNDOPLICATION; SURVIVAL TIME; TRANSBRONCHIAL BIOPSY; VIRUS INFECTION;

CHILD; HUMANS; LUNG TRANSPLANTATION; MONITORING, PHYSIOLOGIC; POSTOPERATIVE CARE;

EID: 34249052267     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e3280991205     Document Type: Review

References (73)

1. Waltz DA, Boucek MM, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric lung and heart-lung transplantation report-2006. J Heart Lung Transplant 2006; 25:904-911. This is a report of vital information regarding pediatric lung-transplant characteristics, statistics, and outcomes.
2. Meyer NJ, Bhorade SM. Evolving immunosuppressive regimens for lung transplant recipients. Semin Respir Crit Care Med 2006; 27:470-479. This is an excellent review of immunosuppressive agents and regimens.
3. Boucek MM, Waltz DA, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report-2006. J Heart Lung Transplant 2006; 25:893-903.
4. Berstad AE, Aalokken TM, Kolbenstvedt A, et al. Performance of long-term CT monitoring in diagnosing bronchiolitis obliterans after lung transplantation. Eur J Radiol 2006; 58:124-131.
5. Schulman LL, Htun T, Staniloae C, et al. Pulmonary nodules and masses after lung and heart-lung transplantation. J Thorac Imaging 2000; 15:173-179.
6. Wallemacq PE. Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem Lab Med 2004; 42:1204-1211.
7. Przepiorka D, Nash RA, Wingard JR, et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999; 5:94-97.
8. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14:147-154.
9. Akhlaghi F, Gonzalez L, Trull AK. Association between cyclosporine concentrations at 2 h postdose and clinical outcomes in de novo lung transplant recipients. J Heart Lung Transplant 2005; 24:2120-2128.
10. Filler G, Feber J, Lepage N, et al. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 2002; 6:411-418.
11. Ragette R, Kamler M, Weinreich G, et al. Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. J Heart Lung Transplant 2005; 24:1315-1319.
12. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24:330-350.
13. Kyllonen LE, Salmela KT. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study. Transplantation 2006; 81:1010-1015. This study suggests that there is no benefit with C2 monitoring as compared with C0 monitoring in pediatric transplant patients and highlights the differences that exist in these studies.
14. Birsan T, Loinig C, Bodingbauer M, et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience. Transplantation 2004; 78:1787-1791.
15. Morton JM, Aboyoun CL, Malouf MA, et al. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant 2004; 23:1035-1039.
16. Schubert S, Abdul-Khaliq H, Lehmkuhl HB, et al. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients. J Heart Lung Transplant 2006; 25:619-625. This study suggests C2 monitoring of thoracic (heart) transplant patients results in fewer cases of acute rejection.
17. Filler G. Value of therapeutic drug monitoring of MMF therapy in pediatric transplantation. Pediatr Transplant 2006; 10:707-711. This study highlights the potential benefits of mycophenolate mofetil monitoring in pediatric patients.
18. Schachter AD, Benfield MR, Wyatt RJ, et al. Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Pediatr Transplant 2006; 10:914-919. This is a study that evaluates immunosuppressive agents in pediatric patients.
19. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004; 36:25S-32S.
20. Kahan BD. Sirolimus-based immunosuppression: present state of the art. J Nephrol 2004; 17 (Suppl 8):S32-S39.
21. Fuchs D, Weiss G, Reibnegger G, et al. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992; 29:307-341.
22. Grebe SO, Mueller TF. Immune monitoring in organ transplantation using neopterin. Curr Drug Metab 2002; 3:189-202.
23. Humbert M, Delattre RM, Cerrina J, et al. Serum neopterin after lung transplantation. Chest 1993; 103:449-454.
24. Humbert M, Roux-Lombard P, Cerrina J, et al. Soluble TNF receptors (TNF-sR55 and TNF-sR75) in lung allograft recipients displaying cytomegalovirus pneumonitis. Am J Respir Crit Care Med 1994; 149:1681-1685.
25. Gebauer BS, Hricik DE, Atallah A, et al. Evolution of the enzyme-linked immunosorbent spot assay for posttransplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2:857-866.
26. van den Boogaardt DE, van Miert PP, de Vaal YJ, et al. The ratio of interferon-gamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients. Transplantation 2006; 82: 844-848. This study suggests that interferon-γ and interleukin-10 ELISPOT monitoring of donor-reactive immunity is a promising tool to individualize immunosuppression in clinical transplantation.
27. Bellisola G, Tridente G, Nacchia F, et al. Monitoring of cellular immunity by interferon-gamma enzyme-linked immunosorbent spot assay in kidney allograft recipients: preliminary results of a longitudinal study. Transplant Proc 2006; 38:1014-1017. This is an additional study suggesting that monitoring interferon-γ ELISPOT donorreactive immunity is a potential tool in clinical transplantation.
28. Zeevi A, Britz JA, Bentlejewski CA, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 2005; 15:17-24.
29. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006; 82:663-668. This study shows the potential of monitoring the immune response as a guide to individualizing immunosuppression regimens, thereby reducing the risk of infection and rejection.
30. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17:77-88.
31. Hooper E, Hawkins DM, Kowalski RJ, et al. Establishing pediatric immune response zones using the Cylex ImmuKnow assay. Clin Transplant 2005; 19:834-839.
32. Gautam A, Morrissey PE, Brem AS, et al. Use of an immune function assay to monitor immunosuppression for treatment of posttransplant lymphoproliferative disorder. Pediatr Transplant 2006; 10:613-616. Although this is a case study, it highlights the potential benefit of monitoring the immune response to guide immunosuppressive therapy.
33. Otulana BA, Higenbottam T, Scott J, et al. Lung function associated with histologically diagnosed acute lung rejection and pulmonary infection in heartlung transplant patients. Am Rev Respir Dis 1990; 142:329-332.
34. Van Muylem A, Melot C, Antoine M, et al. Role of pulmonary function in the detection of allograft dysfunction after heart-lung transplantation. Thorax 1997; 52:643-647.
35. Martinez JA, Paradis IL, Dauber JH, et al. Spirometry values in stable lung transplant recipients. Am J Respir Crit Care Med 1997; 155:285-290.
36. Otulana BA, Higenbottam T, Ferrari L, et al. The use of home spirometry in detecting acute lung rejection and infection following heart-lung transplantation. Chest 1990; 97:353-357.
37. De Vito Dabbs A, Hoffman LA, Iacono AT, et al. Are symptom reports useful for differentiating between acute rejection and pulmonary infection after lung transplantation? Heart Lung 2004; 33:372-380.
38. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heartlung transplantation report-2006. J Heart Lung Transplant 2006; 25:880-892.
39. Kramer MR, Stoehr C, Whang JL, et al. The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy. J Heart Lung Transplant 1993; 12:675-681.
40. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297-310.
41. Reynaud-Gaubert M, Thomas P, Badier M, et al. Early detection of airway involvement in obliterative bronchiolitis after lung transplantation. Functional and bronchoalveolar lavage cell findings. Am J Respir Crit Care Med 2000; 161:1924-1929.
42. Estenne M, Van Muylem A, Knoop C, et al. Detection of obliterative bronchiolitis after lung transplantation by indexes of ventilation distribution. Am J Respir Crit Care Med 2000; 162:1047-1051.
43. Sritippayawan S, Keens TG, Horn MV, et al. What are the best pulmonary function test parameters for early detection of postlung transplant bronchiolitis obliterans syndrome in children? Pediatr Transplant 2003; 7:200-203.
44. Van Muylem A, Verbanck S, Estenne M. Monitoring the lung periphery of transplanted lungs. Respir Physiol Neurobiol 2005; 148:141-151.
45. Weiner DJ, Allen JL, Panitch HB. Infant pulmonary function testing. Curr Opin Pediatr 2003; 15:316-322.
46. Vink GR, Arets HG, van der Laag J, et al. Impulse oscillometry: a measure for airway obstruction. Pediatr Pulmonol 2003; 35:214-219.
47. Guilinger RA, Paradis IL, Dauber JH, et al. The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients. Am J Respir Crit Care Med 1995; 152:2037-2043.
48. Tazelaar HD, Nilsson FN, Rinaldi M, et al. The sensitivity of transbronchial biopsy for the diagnosis of acute lung rejection. J Thorac Cardiovasc Surg 1993; 105:674-678.
49. Trulock EP, Ettinger NA, Brunt EM, et al. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992; 102:1049-1054.
50. Pomerance A, Madden B, Burke MM, et al. Transbronchial biopsy in heart and lung transplantation: clinicopathologic correlations. J Heart Lung Transplant 1995; 14:761-773.
51. Faro A, Visner G. The use of multiple transbronchial biopsies as the standard approach to evaluate lung allograft rejection. Pediatr Transplant 2004; 8:322-328.
52. Knoop C, Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med 2006; 27:521-533. This is an excellent review of rejection in lung transplantation.
53. Sharples LD, McNeil K, Stewart S, et al. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21:271-281.
54. Yousem SA. Significance of clinically silent untreated mild acute cellular rejection in lung allograft recipients. Hum Pathol 1996; 27:269-273.
55. Hachem RR, Khalifah AP, Chakinala MM, et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 2005; 80:1406-1413.
56. Khalifah AP, Hachem RR, Chakinala MM, et al. Minimal acute rejection after lung transplantation: a risk for bronchiolitis obliterans syndrome. Am J Transplant 2005; 5:2022-2030.
57. Glanville AR. The role of bronchoscopic surveillance monitoring in the care of lung transplant recipients. Semin Respir Crit Care Med 2006; 27:480-491. This review nicely summarizes the use of bronchoscopy as a diagnostic modality in lung-transplant patients.
58. Tamm M, Sharples LD, Higenbottam TW, et al. Bronchiolitis obliterans syndrome in heart-lung transplantation: surveillance biopsies. Am J Respir Crit Care Med 1997; 155:1705-1710.
59. Valentine VG, Taylor DE, Dhillon GS, et al. Success of lung transplantation without surveillance bronchoscopy. J Heart Lung Transplant 2002; 21:319-326.
60. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibodymediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033-1041.
61. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74:799-804.
62. Reinsmoen NL, Nelson K, Zeevi A. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transpl Immunol 2004; 13:63-71.
63. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005; 5:131-138.
64. Girnita AL, McCurry KR, Iacono AT, et al. HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004; 23:1135-1141.
65. Vilchez RA, Dauber J, McCurry K, et al. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant 2003; 3:116-120.
66. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of communityacquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5:2031-2036.
67. Larcher C, Geltner C, Fischer H, et al. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant 2005; 24:1891-1901.
68. Lim WH, Russ GR, Coates PT. Review of Epstein-Barr virus and posttransplant lymphoproliferative disorder postsolid organ transplantation. Nephrology (Carlton) 2006; 11:355-366. This is an excellent review discussing the development, progression, diagnosis, and treatment of posttransplant lymphoproliferative disorder.
69. Davis JE, Sherritt MA, Bharadwaj M, et al. Determining virological, serological and immunological parameters of EBV infection in the development of PTLD. Int Immunol 2004; 16:983-989.
70. Benden C, Aurora P, Burch M, et al. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction. J Heart Lung Transplant 2005; 24:2103-2108.
71. Hadjiliadis D, Duane Davis R, Steele MP, et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant 2003; 17:363-368.
72. Cantu E 3rd, Appel JZ 3rd, Hartwig MG, et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78:1142-1151.
73. Benden C, Aurora P, Curry J, et al. High prevalence of gastroesophageal reflux in children after lung transplantation. Pediatr Pulmonol 2005; 40:68-71.